Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
doxazosin alpha-1a adrenergic receptor small molecule NA drugbank , DGIDB Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.65 approved antagonist
doxazosin alpha-1b adrenergic receptor small molecule NA drugbank , DGIDB Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.47 approved antagonist
doxazosin alpha-1b adrenergic receptor small molecule NA drugbank , DGIDB Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.47 approved unknown
doxazosin adrenergic receptor alpha-1d NA Successful target TTD , DGIDB Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.71 approved antagonist
doxazosin adrenergic receptor alpha-1d NA Successful target TTD , DGIDB Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.71 approved unknown
doxazosin alpha-1d adrenergic receptor small molecule NA drugbank , DGIDB Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 2.71 approved antagonist
doxazosin herg human cardiac k+ channel small molecule NA drugbank Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved inhibitor
doxazosin herg human cardiac k+ channel small molecule NA drugbank Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved inhibitor
doxazosin herg human cardiac k+ channel small molecule NA drugbank Hypertensive disease[MeSHID:D006973]
Disease Management[MeSHID:D019468]
Ureterolithiasis[MeSHID:D053039]
Nocturia[MeSHID:D053158]
Urinary tract[MeSHID:D014551]
Ureteral Calculi[MeSHID:D014514]
Benign prostatic hypertrophy[MeSHID:D011470]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved inhibitor
click here to return to the previous page